Description
Prednisolone F tablets contain the active substance dexamethasone. It is a synthetic glucocorticoid (adrenal hormone) that affects metabolism, electrolyte balance and tissue function. Dexamethasone has strong anti-inflammatory and anti-allergic effects, as a result of which it has a beneficial effect on a number of diseases and conditions due to inflammation and allergies.
Prednisolone F is used in diseases that require systemic treatment with glucocorticoids.
These include, depending on the type and severity:
Neurological diseases
Brain swelling caused by a brain tumor, neurosurgery, bacterial inflammation of the meninges (meningitis), brain abscess.
Lung and respiratory diseases
Exacerbation of bronchial asthma.
Skin diseases
Initial treatment of extensive, severe, acute skin diseases, such as erythroderma, pemphigus vulgaris, acute eczema.
Autoimmune / rheumatic diseases
Initial treatment of autoimmune diseases, such as systemic lupus erythematosus (especially affecting internal organs).
Active rheumatoid arthritis with severe progressive course (eg forms that lead to rapid destruction of joints and / or tissues outside the joints. Severe systemic course of juvenile idiopathic arthritis.
Hematological diseases
Blood disorders (eg idiopathic thrombocytopenic purpura in adults
Infectious diseases
Severe infectious diseases with toxic conditions (eg tuberculosis, typhoid), only in combination with appropriate anti-infective treatment).
Prednisolone F is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients and adolescents (over 12 years of age and weighing at least 40 kg) who have difficulty breathing and require oxygen therapy.
Endocrine diseases
Hormone replacement therapy for reduced adrenal function or adrenal dysfunction (adrenogenital syndrome) in adults (applies to Prednisolone F 0.5 mg).
Oncological diseases
Palliative treatment of malignant diseases.
Treatment of some malignancies (eg symptomatic multiple myeloma, acute lymphoblastic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma), in combination with other medicinal products.
Prevention and treatment of postoperative or cytostatic-induced vomiting.
Cerebral edema:
16-24 mg (up to 48 mg) daily orally, divided into 3-4 to 6 separate doses for 4-8 days. For this indication, tablets with a higher content of the drug substance are preferred.
Cerebral edema due to bacterial meningitis:
0.15 mg / kg body weight every 6 hours for 4 days;
in children:
0.4 mg / kg body weight every 12 hours for 2 days, starting before the first antibiotics.
Severe acute asthma attack:
adults 8-20 mg, then if necessary 8 mg every 4 hours.
Children:
0.15-0.3 mg / kg body weight.
Acute skin diseases:
depending on the nature and severity of the disease, daily doses of 8-40 mg are administered, in some cases up to 100 mg, followed by therapy with decreasing doses.
Systemic lupus erythematosus:
6-16 mg / day.
Active rheumatoid arthritis with severe progressive course (eg forms that lead to rapid destruction of joints and / or tissues outside the joints):
12-16 mg / day, in extra-articular manifestations 6-12 mg / day.
Blood disorders (eg idiopathic thrombocytopenic purpura in adults):
40 mg / day for 4 days in cycles.
Severe infectious diseases with toxic conditions (eg tuberculosis, typhoid):
4-20 mg / day for several days, only together with concomitant anti-infective therapy.
Congenital adrenogenital syndrome in adults:
0.25-0.75 mg / day as a single dose.
If necessary, an additional intake of mineralocorticoid (fludrocortisone) is added. In case of special physical stress (eg trauma, surgery), intercurrent infections, etc., it may be necessary to increase the dose 2 to 3 times, and in case of extreme stress (eg childbirth) – up to 10 times increase.
Palliative treatment of malignant diseases:
initially 3-20 mg / day, with longer-term therapy 4-12 mg / day.
Treatment of certain malignancies (eg symptomatic multiple myeloma, acute lymphoblastic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma), in combination with other medicinal products:
the usual dose is 40 mg or 20 mg once a day.
Prevention and treatment of cytostatic-induced vomiting (chemotherapy):
8-20 mg before starting chemotherapy, then if necessary 4-16 mg for 1-3 days.
Prevention and treatment of postoperative vomiting:
a single dose of 8 mg before surgery.
Covid-19 treatment:
Adult patients: 6 mg orally once daily for up to 10 days.
Use in adolescents:
Pediatric patients (adolescents over 12 years of age and weighing at least 40 kg) are recommended to take a dose of 6 mg orally once daily for up to 10 days.
